Priority Antibiotic Stewardship Interventions
Identifying Attributes
Care Settings
Country
Publishing Organisation
Type of Quality Indicator
IOM Quality Dimension
Domain
Defining Attributes
Definition
Proportion of facilities with antibiotic stewardship interventions
Numerator
Number of facilities with antibiotics stewardship interventions
Denominator
Number of facilities
Exclusions
Use of Risk Adjustment
Risk Adjustments
None
Stratifications
None
Collection and Reporting Attributes
Type of Data Collection
Data Collection Methods
Survey
Frequency of Data Collection
Frequency of Data Collection in Days
Reporting Methods
Survey
Reporting Frequency
Reporting Frequency in Days
Indicator Has Recommended Targets
Source and Reference Attributes
Evidence Source
National Healthcare Safety Network, Patient Safety Component - Annual Hospital Survey
Technical Specifications
Link to Measurement Tools
Survey www.cdc.gov/nhsn/forms/57.103pshospsurvblank.pdf (Question 45, 45a: Our facility has the following priority antibiotic stewardship interventions:
Prospective audit and feedback for specific antibiotic agents:
□ Vancomycin (intravenous)
□ Ertapenem, imipenem/cilastatin, or meropenem
□ Ceftazidime/avibactam, ceftolozane/tazobactam, meropenem/vaborbactam, imipenemcilastatin/relebactam, or cefiderocol
□ Fluoroquinolones
□ Daptomycin, linezolid, or other newer anti-MRSA agents
□ Eravacycline or omadacycline
□ Lefamulin
□ Aminoglycosides
□ Colistin or polymyxin B
□ Anidulafungin, caspofungin, or micafungin
□ Isavuconazole, posaconazole, or voriconazole
□ Amphotericin B and/or lipid-based amphotericin B
□ None of the above)